Latest Conference Coverage

Pavel Klein, MD: Brivaracetam is Benign and Efficacious for Focal Seizures

The director of the Mid-Atlantic Epilepsy and Sleep Center also urged physicians to not give up on the search for effective AEDs for their patients.

Kelly Knupp, MD: Treatment Landscape for Lennox-Gastaut Syndrome

The pediatric neurologist and epilepsy specialist at Colorado Children’s Hospital discussed how the treatment landscape for patients with Lennox-Gastaut syndrome could alter if fenfluramine is approved.

William Rosenfeld, MD: Greater Efficacy of Cenobamate With Fewer Concomitant ASMs

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how patients with intractable epilepsy found cenobamate effective.

Christian Meisel, MD, PhD: Treatment Landscape for Seizure Forecasting Devices

The neurologist from Universitätsmedizin Berlin and Berlin Institute of Health provided his insight on the reasons for the limited number of FDA-approved seizure forecasting devices.

Transdermal CBD Efficacious in Children With Developmental and Epileptic Encephalopathies

Efficacy was observed in patients with DEEs such as West Syndrome, Lennox-Gastaut syndrome, and Dravet syndrome.

NeuroVoices: Eric Segal, MD, on Real World Use of Diazepam Nasal Spray

Eric Segal, MD, director of pediatric epilepsy, HMH Hackensack University Medical Center, detailed his study on diazepam nasal spray in patients with and without antiseizure medications.

Positive Fenfluramine Data in LGS Suggest an FDA Approval Is on the Horizon

Kelly Knupp, MD, pediatric neurologist and epilepsy specialist, Children’s Hospital Colorado, detailed the findings of fenfluramine in patients with Lennox-Gastaut syndrome and how it may shake up the treatment landscape.

CBD Effective Regardless of Infantile Spasm History, Fenfluramine Effective in CDD, Wristband Sensor Data May Predict Seizures

Neurology News Network for the week ending December 12, 2020.

Cannabidiol Maintains Efficacy Long-Term in Tuberous Sclerosis Complex

Seizure reduction was observed to be sustained for up to 192 weeks in the Expanded Access Program data.

Christian Meisel, MD, PhD: Expanding Preliminary Data on Seizure Forecasting

The neurologist from Universitätsmedizin Berlin and Berlin Institute of Health spoke about his study presented at AES 2020 and how the next steps following the positive results.

Fenfluramine Shows Clinical Benefit in Dravet for Adults as Well as Children

The US Early Access Program for fenfluramine allowed access to the treatment for patients who were ineligible for clinical trials.

Long-Term Perampanel Efficacious Regardless of Enzyme-Inducing Anti-Seizure Medications

Patients receiving perampanel in combination with an enzyme-inducing anti-seizure medication may require a higher perampanel dose to achieve similar efficacy with only non-EIASMs.

William Rosenfeld, MD: Enduring Efficacy of Cenobamate

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how patients found cenobamate effective for up to 43 months.

SUDEP Rates Greater Than Previously Reported, Higher Among Nonwhite Children

Study data from the NIH/CDC Sudden Death in the Young (SDY) Case Registry suggest that nonwhite children and infants have rates of SUDEP mortality 1.5 times higher than whites.

Personalized Neuromodulation Therapy Reduces Seizures Safely in Drug-Resistant Epilepsy

Microburst stimulation was also found to be more tolerable than standard stimulation in patients with drug-resistant epilepsy.

Eric Segal, MD: Diazepam Clinical Utility Regardless of Concomitant Benzodiazepines

NeuroVoices: Christian Meisel, MD, PhD, on Forecasting Seizures

Christian Meisel, MD, PhD, department of neurology, Universitätsmedizin Berlin, and Berlin Institute of Health, discussed the landscape for devices that forecast seizures, including the use of multi-modal wristband sensors.

Pediatric Epilepsy Laser Ablation Shows Efficacy With Few Complications

The registry is planning to expand, with 5 additional centers recently agreeing to participate and institutional research ethics applications underway.

Cannabidiol Effective in TSC Regardless of Infantile Spasm History

Effect modification analysis showed that the treatment effect when using CBD was comparable between patients with and without infantile spasm history.

Vineet Punia, MD, MS: Initial Data from ELEVATE Trial of Perampanel for Focal Onset Seizures

The neurologist from Cleveland Clinic discussed the potential of using perampanel as a monotherapy for patients with focal onset seizures.

Intermittent Midazolam Administration Yields Return to Functionality for Seizure Cluster Episodes

Data from this post-hoc analysis show slight differences between repeated administration of 1 and 2 doses of midazolam.

Fenfluramine Shows Potential in CDKL5 Deficiency Disorder

No patient with CDKL5 Deficiency Disorder developed valvular heart disease or pulmonary arterial hypertension while being treated with fenfluramine.

Brivaracetam May Improve Quality of Life for Patients With Focal Seizures

Interim data from a real-world study suggest that adjunctive treatment with brivaracetam is well-tolerated and may improve quality of life over 12 months for those with focal seizures.

Both Low- and High-Dose Perampanel Effective and Well-Tolerated

The data suggest that some patients with partial-onset seizures may benefit from lower doses to mitigate treatment emergent adverse events, but these must be tailored to each patient.

Kelly Knupp, MD: Fenfluramine in Lennox-Gastaut Syndrome

The pediatric neurologist and epilepsy specialist at Children’s Hospital Colorado detailed the results of study of fenfluramine in patients with Lennox-Gastaut syndrome.

Diazepam Effective Regardless of Antiseizure Medication Use

The safety profile of diazepam remained similar to what was previously observed, but generally, more patients in the concomitant benzodiazepine subgroup experienced more TEAEs.

William Rosenfeld, MD: Continuing Studies on Cenobamate

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how high rates of seizure reduction were seen in treating drug resistant epilepsy.

Real World Experience Study of Brivaracetam for Focal Seizures Announced

Top line results from the retrospective EXPERIENCE study of brivaracetam are expected to read out in early 2021.

Cannabidiol Efficacy Confirmed in Lennox-Gastaut Syndrome

The GW Pharmaceuticals product has shown confirmed efficacy in LGS, though the study failed to produce a firm conclusion regarding its efficacy in other drug-resistant epilepsies.

Eric Segal, MD: Effects of Diazepam Amid Concomitant Benzodiazepine Use

The director of pediatric epilepsy at the Northeast Regional Epilepsy Group discussed his study presented at AES 2020 which involved the effectiveness of diazepam nasal spray regardless of treatment regimen.